Verdence Capital Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Verdence Capital Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$269K	Sell	12,544 -404	-3%	-$6.19K	0.01%	575
2026 Q1	$180K	Buy	12,948 +415	+3%	+$6.61K	0.01%	613
2025 Q4	$204K	Sell	12,533 -10,331	-45%	-$169K	0.01%	619
2025 Q3	$391K	Buy	22,864 +549	+2%	+$6.69K	0.02%	519
2025 Q2	$260K	Buy	22,315 +1,426	+7%	+$13K	0.02%	586
2025 Q1	$155K	Buy	+20,889	New	+$161K	0.01%	630

Other funds holding ADPT

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

AWM

Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return

FISPB

Fideuram - Intesa Sanpaolo Private Banking Turin $3.33B AUM

KOCAA

Knights of Columbus Asset Advisors New Haven, Connecticut $2B AUM 42.86% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Verdence Capital Advisors's ADPT Position: Q2 2026 in Review

Verdence Capital Advisors reduced its Adaptive Biotechnologies (ADPT) stake by 3.1% in Q2 2026, selling an estimated $6.19K and leaving 12,544 shares worth $269K. The position accounts for 0.01% of the portfolio, ranked #575.

Verdence Capital Advisors first reported a position in ADPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $391K in Q3 2025. 78 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Verdence Capital Advisors held 12,544 shares of Adaptive Biotechnologies worth $269K as of Q2 2026.
Verdence Capital Advisors sold 404 Adaptive Biotechnologies shares in Q2 2026, an estimated $6.19K.
Adaptive Biotechnologies made up 0.01% of Verdence Capital Advisors's portfolio in Q2 2026, its #575 holding.
Verdence Capital Advisors first reported a position in Adaptive Biotechnologies in Q1 2025 and has held it in 6 quarters since.
Verdence Capital Advisors's Adaptive Biotechnologies position peaked at $391K in Q3 2025.
78 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.